Ragini Kudchadkar, MD

Dr. Kudchadkar’s primary interest is in clinical research investigating signal transduction inhibitors in melanoma. Her secondary interest focuses on rare cutaneous malignancies such as basal cell carcinomas.

• Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M. Melanoma, Version 2.2013: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 Apr;11(4):395-407. Pubmedid: 23584343.
• Kudchadkar RR, Smalley KS, Glass LF, Trimble JS, Sondak VK. Targeted therapy in melanoma. Clin Dermatol. 2013 Mar;31(2):200-208. Pubmedid: 23438383.
• Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov;367(18):1694-1703. Pubmedid: 23020132. Pmcid: PMC3549295.
• Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA. Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma. J Immunother. 2012 Oct;35(8):615-620. Pubmedid: 22996367.
• Kudchadkar R, Lewis K, Gonzalez R. Advances in the treatment of Basal cell carcinoma: hedgehog inhibitors. Semin Oncol. 2012 Apr;39(2):139-144. Pubmedid: 22484185.
• Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. J Natl Compr Canc Netw. 2012 Mar;10(3):366-400. Pubmedid: 22393197.
• Smalley KS, Aplin AE, Flaherty KT, Hoeller C, Bosserhoff AK, Haass NK, Bosenberg M, Ribas A, Barnhill R, Kudchadkar R, Messina JL. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res. 2012 Jan;25(1):E1-11. Pubmedid: 22117673.
• Sondak VK, Kudchadkar R. Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?. Oncologist. 2012;17(10):1223-1224. Pubmedid: 23002125.
• Sondak VK, Han D, Deneve J, Kudchadkar R. Current and planned multicenter trials for patients with primary or metastatic melanoma. J Surg Oncol. 2011 Sep;104(4):430-437. Pubmedid: 21858839.
• Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov. 2011 Jun;10(6):411-412. Pubmedid: 21629286.
• Kudchadkar R, Sondak V. Adjuvant interferon: recommit or move on?. Lancet Oncol. 2011 Feb;12(2):112-113. Pubmedid: 21256808.
• Sondak VK, Gonzalez RJ, Kudchadkar R. Adjuvant therapy for melanoma: a surgical perspective. Surg Oncol Clin N Am. 2011 Jan;20(1):105-114. Pubmedid: 21111961.
• Kudchadkar R, Deconti R. Systemic treatments for merkel cell carcinoma. Curr Probl Cancer. 2010 Jan;34(1):97-107. Pubmedid: 20371077.
• Kudchadkar R. Novel targeted therapies for the treatment of metastatic melanoma. Ochsner J. 2010;10(2):117-124. Pubmedid: 21603366. Pmcid: PMC3096194.
• Kudachadkar R, O'Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin. 2005 May;55(3):145-163. Pubmedid: 15890638.
• Gonzalez RJ, Kudchadkar R, Rao NG, Sondak VK. Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. Ochsner J. 2010 Summer;10(2):108-116. Pubmedid: 21603365. Pmcid: PMC3096199.
• Kudchadkar R, Paraiso KH, Smalley KS. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J. 18(2):124-131. Pubmedid: 22453012. Pmcid: PMC3314865.